Screening Options for Preventing Cervical Cancer
Ce dossier présente deux études sur le dépistage du cancer du col de l'utérus, l'une évaluant la performance d'une stratégie de dépistage comportant un examen cytologique basé sur le marquage simultané de la protéine p16 et de l'antigène Ki-67 et comportant le génotypage des papillomavirus humains HPV16/18 (3 225 participantes ; âge moyen : 37,9 ans), l'autre estimant le rapport coût-efficacité de 12 stratégies de dépistage (échantillon de 451 participantes ; âge moyen : 38,2 ans)
Human papillomavirus (HPV) is responsible for approximately 570 000 cases of cervical cancer worldwide every year. Most of these cases of cancer could be prevented, either through early vaccination against high-risk HPV, or by successful screening and management of precursors of cervical cancer. Although childhood vaccination against HPV would be ideal, most women have not received the HPV vaccination and screening for precancerous lesions is generally effective, as long as abnormal results are effectively managed. Despite years of screening, it is still estimated that 13 000 cases of cervical cancer will occur in the United States annually.
JAMA Internal Medicine , commentaire, 2018